Protalix shares dive on Gaucher's drug delay at FDA

Protalix BioTherapeutics ($PLX) reported this morning that the FDA is putting off its deadline for a final decision on its drug for Gaucher's disease. The new deadline is May 1, and the news quickly triggered a fresh drop in the company's share price as investors responded to the delay. Story